Jorey Chernett gains board input rights at Neuronetics (STIM)
Rhea-AI Filing Summary
Neuronetics, Inc. shareholder Jorey Chernett filed Amendment No. 3 to his Schedule 13D, reporting beneficial ownership of 10,588,988 common shares, or 15.22% of the class, based on 69,587,840 shares outstanding as of May 1, 2026. These shares were acquired with personal funds for an aggregate purchase price of approximately $20,682,236, and he holds sole voting and dispositive power over them.
On August 3, 2026, Chernett and Neuronetics reached a “constructive framework for alignment” under which he will have an opportunity to recommend a newly appointed member of the board, subject to customary board approvals and governance processes. Related share transactions and a press release describing the understanding are included as exhibits.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
beneficially owned regulatory
Sole Voting Power regulatory
dispositive power regulatory
Schedule 13D regulatory
constructive framework for alignment regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.